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Objectives. This study was derignrd to *sess the direct e&cts 
of Oosequinsn on myocmlial function. 
Background. Flonquinnn has heen shown to improve sysnp-
tams and exercise tolerance in patients with heart failure. At. 
thweh or&us studies have established that flaseauinan is a I . 
vasoditator, it t, not known to what &mt dirat a&s of the 
drug OII myorsrdial contractility or diastolic properties contribute 
to its beneficial hemadynamic e%ectr. 
Methods. Nitroprusside and intravenws Roseqequlnan were ad. 
ministered sequenttally to I8 patients with were heart failure 
(iYew York Heart Aetiation hnctionat ctasa IIt or IV, tetl 
veotricuhw ejection fraction 0.14 * 0.02). Micromanometer teft 
veotriculsr pressure and rndionuclide volume data werecombined 
to eollstruct pressurwolumo loops dnrmg 1) B h&?&We period, 
2) nitroprusside infusion, 3) a second biweline period, and 
4) Rosequinan i fusion. 
Rerulls. The peak rate of loft ventricular pressure developmoot 
hereased from 899 * 84 to 1,070 2 94 mm Hgk (p < 0.05) with 
Acaquinan. The baseline IeN ventricular end-systoltc prewre- 
volume relatlon was constructed in 15 pattents born the two 
baseline pressure.volumr loops and from that obtained during 
afterload manipulation with nitroprusside. During Roseguinan 
administration, the relation between end.systottc pressure and 
volume was shtfted upward and letlward, indkattng enhanced 
rantractllity, In 14af 15 pntien$ (p < O&31). The nwbnnl rate nf 
decnw in left ventricular pr~ure during tsnvolumetrtc relax. 
ation increased in magnitude with ttaxqutnan from 862 * 63 to 
1,026 f 68 mm li& (p < 0.05). 
Conclusionr. These results tndieste tbat tntra~wnow Rmc- 
quinan hss positive inntropic and lusitropic effects in patientn with 
heart failure. Further shldies M needed to BMOSP Ibe direct 
myacardial etfects of oral tlasequinan. 
N Am Co11 Cardid 1992;20:822-9) 
Flosequinan, an investigational drug with unknown cellular 
mechanism of action, lessens symptoms and increases exer- 
cise capacity in patients with heart failure (l-3). Animal (4) 
and human (5) studies have demonstrated that this drug is an 
arteriolar and venous vasodilator. In patients with heart 
failure, filling pressures decrease and cardiac output in- 
creases after its administration (3,6,7). This improvement in 
pump function has been considered to result from the 
vasodilator actions of the drug. Recently, however, a posi- 
tive inotropic effect of Rosequinan has been demonstrated in 
studies of isolated ferret papillary muscles and anesthetized 
dogs (8.9). In patients with heart failure, noninvasive in- 
dexes of left ventricular contractility were not altered by 
tlosequinan (7). There are conflicting data on the effect of 
oral Aosequinan an the rate ofrise ofleft ventricular pressure 
(peak positive dP/dt) (IO,1 I). The etfectr of floaequinan on 
myocardial diastolic properties have not been previously 
investigated in humans. Thus it is not known to what extent 
the improvement in pump function with Ausequinan in 
patients with heart failure reflects alteration of myocardial 
contractile and diastolic function rather than the peripheral 
vasodilator effects of the drug. 
Assessment of the inotmpic effect of an agent that is also 
a vascdilator has been difficult because most indexes of 
contractility are sensitive to changes in loading conditions 
(12). The left ventricular end-systolic pressure-volume rela- 
lion has emerged as a relatively load-independent measure af 
inotropic function (U-17). and it has been applied to the 
evaluation of new agents for the treatment of heart failure 
(18-20). In the mesent studv. we used the end-svstalic 
pressure-volume ;elation to d&ermine whether Rose&an 
has a direct effect on myocardial contractile function inde- 
pendent of its etTects on loading conditions in patients with 
heart failure. Indexes of diastolic function are alao inilu- 
enced by loading conditions as well as by intrinsic myocar- 
dial properties (21-26). Therefore, to determine whether 
flosequinan has a direct intluence on myocardial diastolic 
properties. we compared its effects on indexes of diastolic 
function with those of the “pure” vasodilator nitroprusside 
(27,283. 
Methods which we the Fick oxvee” method war used. Calculations 
Patient% The study protocol mandated that parients have were made by using thefollowing fornx&s: Cardiac index 
New York Heart Association functiona! class 111 or IV heart (brewmin per ml) = (Cardii output)/(Body surface area); 
failure for at least I month before entry, radionuclidc Systemic vawlar resistance (dy”es%cm5) = 8CiMean sys- 
left ventricular ejection fraction <0.40. systolic blood preo 
temic arterial pressure - Mean right atrial pressure)l(Cardii 
sure 290 mm Hg and pulmonary capillary wedge pressure 
output): Pulmonary vascular wsisiance tdynesslcms) = 80 
>I2 mm Hg. There were 16 me” and 2 women. aged 
(Mean pulmonary tiedat t,ressure - Mean pubnonary cap% 
63 -C 2 (mean -+ SEM) years. Seven patients were in New 
lay wedge pressure)/(Cxdiae output); Stroke volume (“II) = 
York Heart Association class 111 and tt were in class tV 
(Cardiac output)l(Heart rate); Stroke volume index (mVm2) = 
despite treatment with digoxi”. diuretic agents and vasodi- 
ICardiac i”dexHHeart rate): and Stroke work index fg - mim*) 
lators (including captopril in 17 patients). Mean left ventric- 
= (0.0136XMean systemic rntcrial pressure - Left ventricular 
ular ejection fraction was 0.14 ? 0.02. Thirteen patients 
end-diastolic pressure@troke volume index). 
had coronary artery disease. three (Patients 6, IO and IS) 
The logarithmic time constant of left ventricular isovotu- 
had idiopathic dilated cardiomyopathy, one (Patient I71 had 
metric relaxation(T,)wascalculatedfor 16patientsfmmthe 
mitral valve replacement for rheumatic mitral regurgitation 
micromanometerdetennined left ventricular pressure by the 
and one (Patient 18) bad cardiomyopathy after myocarditis. 
method of Weirs et al. (29). The period of inovolumetric 
relaxation was taken to be from the aortic dicmtic notch 
Thirteen patients had normal sinus rhythm and five (Patients 
3, 8, 9, I5 and 17) had atrial fibrillation. The study prorocol 
pressure to the pressure corresponding to the peak of the V 
was approved by the institutional Subcommittee on Human 
wave of the simultaneous pulmonary capillary wedge trac- 
Studies on June 27, 1989. and informed consent was ob- 
ing. T, was defined as the negative reciprocal of the slope of 
the linear fit of In (left ventricular pressure) versus time. It 
mined from all patients. was not measured in Patient 16, the patient without a 
Pmtned. Digoxi”, diuretic agents and vasodilators were micromanometer catheter, or in Patient 8 because of a 
withheld for 8 to 24 h before cardiac catheterization. Pre- technical acquisition error. The derivative time constant 
medicaion was not given. Left heart catheterization was (To) was calculated for I1 patients by the method of Raffand 
perforated from the femoral approach by using a microma- Glantz (30) during the same time interval as T, as the 
nometer-ripped catheter (Miller Instruments) in 17 patients negative reciprocal of the slope of a linear tit of left ventric- 
and a fluid-filled catheter in I (Patient 16). Right heart “tar dP/ dt versus pressure (30). This method allows for a 
catheterization was performed from the right internal jugular “on-zero pressure asymptote. The derivative time constant 
vein with a triple-lumen themtndilutio” catheter. Three could not be calculated for the patient without a microman- 
patients (Patients 9, IS and 17) with atrial fibrillation and ometer catheter (Patient 16) or for six patients (Patients 3,5, 
marked variability in RR intervals underwent fixed rate right 7. 8, I4 and 16) whose dP/dt tracings were inadequately 
ventricular pacing throughout the cnurse of the protocol. approximated by a monoexpon%ntial function. 
After baseline data were collected. nitroptussidc infusion Gated blood pool imaging. After in viva labeling of pa- 
was begun at a dose of 10 to 25 &nin and titrated to achieve tient red blood cells with 20 mCi cf technetium&%“, supine 
a IO- to XI-mm Hg decrease in mea” arterial pressure. Data gated blood pool images were acquired in the anterior and 
were collecled during the nitmpmsside infusion and again left anterior oblique views; 2oO.wO counts were collected for 
10 min after discontinuation of ntiroprusside when arterial the anterior view (16 frames) and _%%l.tXIl counts for the left 
pressure bad returned to its baseline value. Flosequinan anterior oblique view (32 frames). The timing of the first 
infusion was then begun at a t-ate of 5 mtimin. If mean frame of the scan corresponded to the peak of the R wave of 
arterial pressure did nit decrease by IO to 2fimm Hg within 
4 min. the infusbn rate was increased to 10 mg’min. Data 
were recorded during Rosequinan infusion. The total dosage 
of Rosequinan was limited by protocol design to IW mg in 
the tirst two patients and to 150 mg in subsequent patients. 
Serum “orepinephrine levels were measured during each 
treatment period in 13 patients (the exceptions are Patients 
I, 2, IO, 14 and 16). 
Hemodyonmk measuremmts. The following hemody- 
nandc variables were recorded: heart rate, right atrial pres- 
sure, mes” pulmonary riflery pressure, pulmonary capillary 
wedge presrure. left ventricc’~ pressure. mean systemic 
arterial pressure and. in patients with micromanometer- 
tipped catheters, left ventricular dP/dt (by electronic differ- 
entiation). Cardiac outout was obtained bv the tbemodilu- 
the electrocardiogram (EC@, which ias recorded simulta- 
neously on the pressure tracings. The acquisitions were 
normalized to the fmnx with the maximal nun&a of counts. 
A time-activity curve of the left ventricle was constructed by 
using a semiautomated edge detection method with a vari- 
able region of interest. Background count density was czd- 
cula;ed from a” area adjacent to the left ventricle and was 
subtracted from each area of interest. Ejection fraction was 
calcutared as (Stroke counts)/(Enddiastolic counts). 
Baseline left ventricular end-diastolic volume was calcu- 
lated from the anterior and left anterior oblique views by 
using a previously validated geometric biplane area-length 
method (31.32). Volumes at other time points in the cardiac 
cycle and during subsequent scans were alcula!ed from the 
left anterior oblique scan as the baseline end-diastolic vol- 
tion technique unless t&pid regurgitari~n was present, in ume multiplied by the rario ofsounts in a panicular frame to 
counts in the baseline end-diastolic frame. Images were 
acquired only in the left anterior oblique projection during 
and after nitroprusside infusion and during Roscquinan infu- 
sion. Patient and camera movement were avoided between 
treatment periods. The time-activity curve was smoothed by 
using * 3.point moving average (coefficients 0.25.0.50,0.20. 
The lime-activity curves during and between drug interven- 
tions were corrected for differences from the baseline in 
acquisition time and frame interval, and for biologic and 
physical decay of the isotope. Because of technical errors, 
radionuclidc images suitable for determination of lefi ven- 
tricular volumes were not obtained in Patients 8, 13 and 18. 
In three patients (Patients I, 3 and 5). volumes throughout 
d&stole were not obtained because of technically inadequate 
acquisitions. The radiation exposure for each pa:icnl was 
that of Auoroscopic catheter placement and B standard 
radionuclide ventriculogmm. 
Pressure-volume analysis. Left ventricular pressure mea- 
surements from four representative consecutive beats et the 
midpoint of the gated scan were digitized at a sampling 
interval of 2 ms on a Summagraphics MM1812 Bitpad 
interfaced to a VAX 780 compuler. Average pressure was 
measured at the same irame interval as for the radionuclide 
images. Pressure-volume loops were constructed by plotting 
these pressures with their corresponding volumes, starting at 
a simultaneous time point (the peak of the R wave of the 
ECG). 
The baseline end-systolic pressure-volume reitdion WE 
constructed from the two baseline pressure-volume loops 
and the loop constructed daring nitroprusside infusion by the 
iterative method of Kass et al. (33). Points from each loop 
where the ratio of pressure to volume was maximal were 
selected. and linear regression analysis of these points was 
performed. To avoid giving disproportionate weigh1 to the 
two baseline measurements, they were each given B weight 
half that of the measwcment during nitroprusside infusion. 
The extrapolated volume-axis intercept at zero pressure was 
determined from the regression analysis. Points on each loop 
for n:dch the pressure divided by the difference between the 
corresponding volume and the volume-axis intercept was 
maximal were then selected. and a new pressure-volume line 
(with a new volume-axis interccut) generated. This mocess 
was repeated until there was no‘chaigc in slope or &me- 
axis intercept. In Patient 6. images were not obtained durine 
the second baseline period, so ihat the baseline end-systolic 
pressure-volume relation was calculated lrom the first base- 
line and nitroprusside loops only. 
A change in ovemll left ventricular distensibility during 
nilroprusside or flosequinan infusion was defined as a prcs- 
we diierence of 83 mm Hg in overlapping portions of the 
passive filling phase of the left ventricular diastolic pressure- 
volume relation. 
Siatisties. Data are expressed as mean value 2 SEM. 
Comparisons among the four treatment periods were made 
by two-way analysis of variance and subsequent compti- 
sons by the Newman-Keuls test (341. The cumulative bino- 
mial distribution test was used to assess the significance of 
the shift of the end-systolic point during the flosequinan 
infusion from the baseline end-systolic pressure-volume 
relation. Differences of p < 0.05 were considered significant. 
Results 
Baseline measurements. Mean hemodynamic values are 
summarized in Table I. Left ventricular end-diastolic prcs- 
sure was elevated and cardiac index wes depressed in both 
baseline periods. Right atrial pressure was slightly higher in 
the second than in the first baseline period. There were no 
other significant differences between the two baseline peri- 
ods in any of the measured or derived variables. 
Hemodynamic responses to nihoprwide and Rasequinan. 
During nitroprusside infusion (101 ? 16 &min), mean 
systemic arterial, right atrial, pulmonary artery and capillary 
wedge pressures and systemic and pulmonary vascular re- 
sistance values all decreased. Left ventricular end-diastolic 
pressure decreased from 28 * 2 lo 19 t I mm Hg (p < 0.05). 
Cardiac index increased from I.8 z 0.1 to 2.1 t 0.2 
literslmin per m2 (p < 0.051, whereas heart rate did not 
change. Flosequinan infusion (10 mglmin; total dose to0 mg 
in Patients I and 2, 150 mg in subsequcr! patients) also 
resulted in decreases in mean systemic arterial. right atrial, 
pulmonary artery and pulmonary capillary wedge pressures 
and systemic and pulmnnary vaxular resistance values. Left 
venlricular end.diastolic pressure decreased from 30 ? I to 
24 t 2 mm Hg (p < 0.05). Cardiac index increased from I.8 
+ 0.1 lo 2.6 t 0.1 litersimin per m’(p < O.M), whereas bean 
rate increased sliehtlv. When the three pxients with fixed 
rate ventricular peeing were excluded, he& rate was 91 + 4 
beatslmin during the first baseline period. 90 f 3 with 
nitmprusside (p = NS). 92 * 3 during the second baseline 
period and % f 4 with Rosequinan (p < 0.05 vs. second 
baseline and vs. nilroprusside). 
Comparison of the etTects of Aosequinan with those of 
nitropmsside reveals a higher afterload (as judged by mean 
systemic arterial pressure and systemic vascular resistance) 
and preload (as judged by left ventricular end-diastolic 
prcssure~ with flosequinan, a lower stroke volume index with 
Rosequinan, and comparable cardiac index and stroke work 
index with the two drugs. Although right atrial pressure was 
higher with Rosequinan than with silroprussidc, tbe change 
from the preceding baseline value was similar with the two 
drugs. Leh ventricular ejection fraction increased by an 
identical amount with Rosequinan and niiroprusside. Heart 
rate increased only with Rosequinan, despite tbe smelter 
decrease in mean systemic arterial pressure: thus. the in- 
crease could not he attributed to reflex changes in autonomic 
tone. 
Effect of Aasequinan cm contractility. Peak positive left 
ventricular dP/dt was unchanaed with nitroorusside but 
increased with flosequinan (8.99~ 84 to 1.070 k.94 mm Hgis. 
p c 0.05): this index increased in 16 of tbe 17 patients in 
whom it was measured. Pressure-volume lwps. constructed 
for 15 patients, are shown in Figure I. In 14 of the I5 patients 
(the exception is Patient 3), the end-systolic portion of the 
Roscquinun loop was shifted upward and leftward from the 
baseline end-sy&lic press&volume relation Up < 0.001). 
This shift indicates an imorovement in systolic oerformance. 
which cannot be adequately accounted for by a reduction in 
afterload and therefore reflects enhanced myacardial con- 
tractility. 
EiTects of nitroprusside and Rosequinan on diastolic func- 
tion. The magnitude of peak negative left ventricular dP/dt 
was unchanged with nitmprusside but increased with Rose- 
quinun in I6 of I7 patients. The value for the loaarithmic 
time constant decreased with both nitroprusside and flose- 
quinan, whereas the derivative time constant did not change 
by a statistically significant amount with either drug. The left 
ventricular diastolic pressure-volume relation could be con- 
structed in 12 patients. In eight of these patients, there was 
insufficient overlap of the diastolic pressure-volume rcla- 
tions during the first baseline and nitroprusside periods to 
allow meaningful assessment of changes in overall left ven- 
tricular distensibility. In the four patients who did have 
overlap of the diastolic pressure-volume relations (Patients 
2, 4, 9 and IO), the relation was shifted downward with 
nitroprusside. Similarly, the diastolic pressure-volume rela- 
tion during the tlosequinan infusion overlapped the relation 
during the second baseline period only in P&uts 7 and 16. 
These two patients had a downward shift in the relation 
during llosequinan infusion. 
Side effect?.. One patient (Patient 9) had bradycardia and 
hypotension during nitroprusside admirirtration. These re- 
solved after discontinuation of the drug and ine aunurusna- 
tion o;atmpine. Nitraprusside was reinstituted after IO min 
at a lower dose without further adverse effects. No side 
effects were observed during the administration of tlone- 
quinan, but one patient (Patient 51 had a cardiac arrest 6 h 
after completion of the study. Tbe initial rhythm was WI- 
tricular tachvcardii. Resuscitation was unsuccessfid. Post- 
murtem examination showed severe three-vessel coronary 
atherosclerosis. prior myocardial infarction. fibrosis and 
biventricular enlargement. 
Discussion 
Inntropic effect uf tlmequittan. Previous studies (3,6,TJ 
have shown that the oral administration of flosequinan to 
patients with heart failure results in braeases in cardiac 
index and stroke volume index and decreases in right atrial. 
pulmonary capillary wedge and systemic arterial pressures. 
This improvement in cardiac pump performance has been 
attributed to afterload reduction (I-3.6.7). Recently, how- 
ever, two groups of investigators found that Rosequinan 
incrra\ed tension deve!opeent in isolated ferret pnpi!!ary 
muscle (8,Y). Intravenous (8) or intraduodenal (9) adminis- 
‘ration of flosequinan tu anesthetized dogs resulted in an 
increase in peak positive left ventricular dP/dt: this effect 
was not blocked by propranolol(8). 
Figure 1. Left ventricular pressure-volume lwps demonstrating that 
Rosequinan i fusion was associated with a leftward and upward shift 
fromthe baseline nd-systolic pressure-volume relation, indiating a 
positive inotmpic ~&EL in 14 uf 15 patients (Patient j is the 
exception). The solid line represeds the baseline end-systolic 
pressure-volume relation and was constructed from the first and 
second bsselinc and nilroprusride (NIPRIDE) loops by an ltealive 
method (see tex0. 
In a study of patients with heart failure, flosequinan did 
not alter noninvasive indexes of left ventricular contractile 
function (7). There have been two left heart catheterization 
studies of oral flosequinan in hum,ms. Rieggcr et al. (IO) 
administered 100 mg to 10 patients with only moderately 
severe heart failure (mean left ventricular ejection fraction 
0.44). After 90 min. left ventricular end-diastolic pressure 
decreased, whereas cardiac index and peak positive left 
ventricular dP/dt were unchanged (IO). Corin et al. (11) 
administered the same dose to 10 patients with more ad- 
vanced heart failure and obtained hemodynamic nt~asttre- 
ments 64 min later. In their study as well, left ventlicular 
end-diastolic pressure decreased but cardiac index in- 
creased. Peakepositive left ventricular dP/dt in the group 
increased from 940 + IS0 to 1,050 t 240 mm Hds (p < 0.0% 
even though it decreased in 2 of the IO patients, a finding 
attributed bv the inves1ieato.s to a concomitant reduction in 
preload. As’these two studies uemonslrate. the load de&w- 
dence of neak oositive left ventricular dP/dt makes it an 
imperfect index of contractility. 
The present study was designed to assess the effect of 
Rosequinan on myocardid Ico!mpi: s:z.:e by utiiizing the leit 
ventricular end-systolic pressure-volume relation, a rcla- 
tively load-independenl index of contractile function i:f 
17). We have previously shown (35) that this relation is linear 
with tlosequman would, if anything. reduce the magnitude of 
left ventricular peak negative dPldt .4!ihoogh bw-t rste 
inc~caed unb Rosequinan. the chanse was much toa ,mall 
to account for the increase in Peak negative left ventricular 
dP/dt. Thus the increase in magnitude of this index indicates 
that Rosequinan exerts a positive lusitropic effect. that is, a 
hen&al mfluence on myocardial relaxation. A similar 
effecl has been obwwd for the phorphcdiesterase inhibitor 
enoximone (28). 
We attempted 10 assess overall left ventricular disrensv 
bility throughout diastole by examining the left ventricular 
diastolic pressure-volume relation. However, marked de- 
creases in left ventricular volume obviated comparison of 
di::!olic :resrun over a commot! range of volume for the 
second hawlise and flosequinan periods in all but two 
patients: in these oatients, a downward shift of the relatmn 
was observed with Rosequinan. 
in the range of pressures associated with rhe adminlstratlon 
of nitroprosside to patienrs with sex:e bean fai!nre. We and 
others have utilized end-systolic pressure-volume analyris !c 
demonstrate inotropic effects of agents Fuch as phosphodl- 
esterase inhibitors (18.19) and calcium channel antagonists 
(20) in this patient population. Because of the time con- 
straints inh.&m in~a~complex left heart catheterization 
study. we administered flosequinan by the mtravenous 
route. We found in 14 of 15 panenls that Rosequinan shifted 
the end-systohc portion of the left ventricular pressure- 
volume loop upward and leftward from the baseline end- 
systolic presswxolume relation derived by manipulaiing 
afterload with nitroprusside. Also because of time con- 
straints. we did not independently vary afterload with nitro- 
prusside during Aosequinan infusion. Thus we dtd not con- 
struct the entire end-systolic pressure-volume relation with 
Rosequinan and could not determine whe:her this drug 
altered the slope or intercept (or both). Rather, we con- 
cluded that because the left vantlicular end-systolic volume 
during Rosequinan infusion WBE lower than thzat accounted 
for on the basis of afterload reduction alone, Rosequinan 
exerted a positive inotropic effect in these patients. 
Effect on diastolic function. Greenberg and Touhey (9) 
reported that Rosequinan did noi affect the rate of relaxation 
of isolated ferret papillary muscle but did increase the 
magnitude of peak negative left ventricular dP/dt in anesthe- 
tized dogs. The prewd rtxdy is the first to RUSE the effect 
of Rosequinan oo myocardial diastolic function in humans. 
Evaluation ofdiastolic function is problematic because wail- 
able indexes assess different aspects (relaxation, filling, 
compliance) of diastolic pafom~ance. Furthermore, indexes 
of diastolic function may be affected by loading conditions 
(21-26). Previous studies (21.22.28) have demonstrated ben- 
eticial &cts of the “pure” vasodilator nitroptusside on 
indexes of diastolic function in patients with heart failure. 
We reasoned that a direct et&t of flosequinan on diastolic 
properties of the myocardium would be manifest as an effect 
beyond that of nitroprusside, and we therefore compared the 
influences of these two agents on indexes of diastolic func- 
tion. 
The value for the logarithmic time constant T, decreased 
with both nitmprussidc and Rosequinan. as did indexes of 
preload (let? ventriculsr end-diastolic pressure and volume) 
and afterload (mean systemic anerial pressure and systemic 
vascular resistance). The decrease in the logarithmic time 
constant with both agents may be due to a downward 
translation of the ventricular pressure curve. which obliga:es 
shortening of the time constant of relaxation in a model that 
constrains the pressure asymptote to be 0 136) The L‘Z%Z- 
itant decrease in the &riratwe time constant To with 
ni!roprusstde and Rosequinan was not statistically sintificant 
for either drug. Mhaugh the magnitude of peak negative left 
ventricular dP/dt was not altered by nitroprurside, this index 
of relaxation increased in magnit~dc with tlosequinan. This 
increase cannot be attributed to change: in loading condi- 
tions because the diminished preload and afterload observed 
Limitatiollg of the stndv. The use of a studv orotocol 
ioco;lruraing left heart caiheteri.*ation enabled is’to fully 
assess contractile and diastolic function, but it impaxed time 
constraints that limited the waluation in several ways. Some 
of these bmi:xioos have already been acknowledged. In 
addition. pressure-volume loops from odf two afterload 
states were used to construct the baseline end-systolic 
pressure-volume relation. This method is based on the 
previously validated assumption that the end-systolic 
pre9w:-wl~~mP relation is !ineir i,i the re!:rant axe of 
pressure in patients with severe heart failure (35). 
Also because of time constraints, we administered flose- 
quinan in intravenous rather than in oral form. When zdmin- 
istered orally. Rosequinan is rapidly converted to a sulfone 
mctnbolite (371. which has both vasodilator and inotropic (8) 
actions. We did not measure serum levels of Rosequinan or 
its metabalite. It is possible that the positive inotropic and 
lusitropic eicts that we observed were associated with 
higher plasma levels of Rosequinan than are achieved with 
o&xl administration of the drui. Therefore, we cannot draw 
conclusions from our study regarding the myocaniial effects 
of oral flosequinan. It is noteworthy, however. that Corin et 
al. (I I) observed an increase in peak positive lefi ventricular 
dPldt in 7 of IO patients with heart failwe after an oral 
tlosequinan dose of 100 mg. 
The validity of absolute radionuclide left ventricular 
volume mearoremertts has not been assessed in patients with 
severe heart failure. However, the conclusions of this study 
rest solely on relative left ventricolar volumes in the com- 
parison of study periods and do not depend o” absolute 
volumes. 
Meehnnismofactiort. The cellularmechanismofactionof 
flosequinan is the subject of ongoing investigation. Flose- 
quinan has direct positive inotropic. lusitmpic and chmno- 
tropic effects on the myocardium. The actions of other 
agents. stich as beta-adrenergic receptor agonists and phos- 
phodiestemse inhibitors that exert positive inotmpic, Iusi- 
tropic and chronotropic effects are mediated by an increase 
in the intracellular concentration of cyclic adenosine mona- 
phosphate (AMP). Although cyclic AMP levels in tissue 
from guinea pig ventricles increased in response to flose- 
quinan. this result occurred only at high concentrations of 
the drug (38). Because the inotropic effect of the drug has 
been detected in guinea pig atria (38) and isolated papillary 
muscle (8,9), and persists despite beta-adrenergic receptor 
blockade in papillary muscle (8,9) and the intact dog (81, it 
does not appear to be mediated by direct or indirect stimu- 
lation of beta-receptors. This conclusion is corroborated in 
part by the lack of change in plasma norepinephrine concen- 
tration during flosequinan infusion in the present study. 
Although phosphodiesteraee inhibition by flosequinan has 
been detected, this phenomenon has been observed at high 
dtug concentrations and is nonspecific with r~pect to phor- 
phodiesterase isoenzyme type (38). Furthermore. prelimi- 
nary data in isolated human cardiac muscle indicate that the 
adenylate cyclase stimulator forskalin potentiates the con- 
tractile response to the phosphodiesterase inhibitor milri- 
none but not that to flosequinan (39.40). Although it has been 
suggested that the effect of Rosequinan on vascular smooth 
muscle is mediated by antagonism of protein kinase C (41). 
the role of this system in cardiac muscle remains specula- 
tive. 
Summary and conclusions. We have shown that iuttwe- 
nws Rosequinan has positive inotropic and lusitmpic ef- 
fects. in addition to causing systemic vasodilation, in pa- 
tients with severe heart failure. The cellular mechanism of 
action of Aosequinan is unknown and may be distinct fram 
that of two classes of drugs, beta-adrenergic receptor ago- 
nists and phosphodiesterase inhibitors, that increase heart 
rate, enhance contractility and speed relaxation in patients 
with hart failure. Further studies are required to determine 
whether long-term oral administration of flosequinan is as- 
sociated with direct myocardial effects. 

